Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that Medicare rules in the United States and new regulations in Europe and Japan will cause physicians to alter their prescribing habits and will limit the uptake of new therapies for Parkinson's disease.

The new Pharmacor report entitled Parkinson's Disease finds that Medicare Part D rules in the United States and cost-containment regulations in Europe and Japan have changed the reimbursement environment, making it very difficult for new treatments to unseat the dominant players in the market, including Bristol-Myers Squibb's Sinemet IR and CR, Boehringer Ingelheim's Mirapex, and GlaxoSmithKline's Requip.

However, novel therapies will launch with new mechanisms of action that treat nondopaminergic symptoms of Parkinson's disease and motor complications caused by Sinemet treatment. These promising emerging therapies such as Merck KGaA's sarizotan and Kyowo Hakko Kogyo's istradefylline, will provide medical benefit to patients and will earn significant sales.

"The cost vigilance of payers will dramatically limit the pricing, reimbursement, and uptake of new drugs that do not differentiate themselves from earlier-to-market competitors and their generic alternatives," said Julie Kerner, Ph.D., analyst at Decision Resources, Inc. "Only new drugs that can show better efficacy or novel mechanisms of action compared with currently-available Parkinson's disease therapies will succeed."

About Parkinson's Disease

Parkinson's disease is characterized by motor symptoms such as tremor, muscle rigidity, gait dysfunction, and postural instability. In the major pharmaceutical markets, Parkinson's disease ranks as one of the most common chronic, progressive motor system disorders in the elderly. In the United States, the prevalence of the disease is 7.4 cases per 1,000 people.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

FDA Approves First Cervical Cancer Vaccine

View Now